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Abstract
Background: The balance between muscle regeneration and ongoing degeneration is a relationship that greatly
influences the progression of muscular dystrophy. Numerous factors may influence the muscle regeneration, but
more information about the relationship between genotype, clinical severity and the ability to regenerate is
needed.
Methods: Muscle biopsies were obtained from the tibialis anterior muscle, and frozen sections were stained for
general histopathological and immunohistological evaluation. Differences between groups were considered
statistical significant at P < 0.05 using Student’s unpaired t-test.
Results: We found that all patients with limb-girdle muscular dystrophy type 2I (LGMD2I) had a large number of
internally nucleated fibers, a sign of previous regeneration. The level of expression of muscle-specific
developmental proteins, such as neonatal myosin heavy chain (nMHC) and myogenin, was related to the clinical
severity. Additionally, we found that the majority of nMHC-positive fibers did not stain positively for utrophin in
patients who were compound heterozygous for the L276I mutation, suggesting that the predominant form of
regeneration in these patients is fiber repair rather than formation of new fibers. Double staining showed that
many smaller nMHC-positive fibers were positive for antibodies against the glycosylation on a-dystroglycan,
suggesting that such glycosylation may be a result of muscle regeneration.
Conclusion: Severely affected patients with LGMD2I have a high level of muscle degeneration, which leads to a
high rate of regeneration, but this is insufficient to change the imbalance between degeneration and regeneration,
ultimately leading to progressive muscle wasting. Detailed information regarding the level and rate of muscle
regeneration and potential obstructions of the regenerative pathway should be of use for future therapies
involving satellite-cell activation.
Background
Limb-girdle muscular dystrophy type 2I (LGMD2I) was
molecularly characterized in 2001 as caused by muta-
tions in the gene for fukutin-related protein (FKRP) [1].
It has been suggested that FKRP is involved in glycosyla-
tion of a-dystroglycan (a-DG) [2], a protein that stabi-
lizes the link between the contractile apparatus and the
extracellular matrix (ECM) [3]. Although it is believed
to possess enzymatic properties, the exact function of
FKRP has not yet been elucidated. It has been suggested
that mutations affecting the translocation of FKRP from
the endoplasmic reticulum to the Golgi apparatus
invariably lead to severe phenotypes, whereas mutations
that do not affect lodging of FKRP in the Golgi mem-
brane may lead to moderate phenotypes [4]. However,
other investigators have suggested that the main patho-
genic mechanism relates to a lack of interaction between
FKRP and its substrate(s) in the Golgi [5].
In Denmark, LGMD2I accounts for 40% of the total
number of recessively inherited cases of LGMD2 [6].
Most patients with LGMD2I are homozygous for the
mutation L276I (826A>C transversion). This genotype is
generally associated with a mild phenotype, whereas
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tion generally display a more severe phenotype [7,8].
There is no known substitute for FKRP, and loss of its
function in LGMD2I leads to degeneration of myofibers
and secondary loss of proteins that are important for
structure and function, such as a-DG and merosin [9,10].
To counterbalance degeneration, a muscle must regener-
ate its fibers, and establishing the regenerative response
to muscle damage in muscular dystrophies may provide
important clues to therapeutic interventions.
In general, muscle damage leads to activation of quies-
cent satellite cells residing between the sarcolemma and
basal lamina. Once the satellite cell has fused with the
myofiber, its nucleus migrates to the site that requires
repair. This migration is visible histologically as intern-
ally nucleated fibers, and counting these has traditionally
been one way of determining muscle regeneration [11].
However, internally nucleated fibers may not fully
explain the temporal pattern of a regenerative response
to ongoing degeneration, because internal nuclei can
reside in the cytoplasm of myofibers for several months.
In this study, we determined the temporal regenerative
response to muscle degeneration in patients with LGMD2I,
using developmental and myogenic markers that are only
expressed for days or weeks, such as MyoD (0 to 2 days)
and myogenin (1 to 7 days), neonatal myosin heavy chain
(nMHC, 1 to 3 weeks) and utrophin (weeks to months)
[12-14]. We assessed the recent regeneration in muscle
fibers of patients homozygous and compound heterozygous
for the L276I mutation, and correlated this with the age at
biopsy and duration of LGMD2I in patients, as the capacity
to regenerate normally decreases with age [15].
Methods
The study was approved by the Scientific Ethics Com-
mittee of Copenhagen and Frederiksberg Counties
approved this study, and all patients provided informed
consent.
Patients
In total, 22 patients with LGMD2I participated in the
study (Table 1). Clinical onset was defined as the first
time patients noticed symptoms such as decreased walk-
ing distance, muscle pain after physical exertion, trouble
walking up stairs, rising from a seated or crouched posi-
tion, and tendency to fall. Of the 22 patients with
LGMD2I, 17 (eight male, nine female; mean ± SD age
44 ± 14 years, range 23 to 65 years) were homozygous
for the L276I mutation and had disease onset at 19 ± 11
years of age (range 2 to 36 years). Six of these patients
had disease onset in childhood, and the rest had a later
onset. Duration of illness was defined as the period
from age at onset to age when the biopsy was taken.
The remaining five patients (one male, four female;
mean ± SD age 27 ± 12 years, range 13 to 40 years,)
were heterozygous for the L276I mutation, and their
disease onset occurred at 6 ± 4 years of age (range 3 to
12 years). Muscle morphology was evaluated in samples
from the tibialis anterior. The strength of ankle dorsal
flexion was therefore tested by dynamometry and used
as a measure of clinical severity for the biopsied muscle
[16]; it was normalized to the ankle dorsal flexion (196
± 52 N) determined in healthy subjects (14 male, 13
female; age 32 ± 12 years, range 16 to 59 years). From
this group, six healthy controls (three female, three
male; age 45 ± 11 years, range 31 to 55 years), formed
the control group for all histology and immunohistology
in the study.
Muscle biopsy
Muscle biopsies were obtained from the tibialis anterior
muscle by percutaneous needle biopsy technique using a
5-mm Bergstrøm needle. Biopsies were snap-frozen in
isopentane, cooled in liquid nitrogen, and stored at -80°
C before being cut into sections on a cryostat.
Histology and immunohistochemistry
Sections 10 to 12 μm thick were stained with hematoxy-
lin and eosin (H&E) for general histopathological eva-
luation and assessment of internal nuclei, defined as
non-peripheral internal nuclei. Full sections were evalu-
ated for the percentage of internal nuclei, necrotic and
ring fibers, and the level of fibrosis and muscle-fat infil-
tration. A myofiber was considered internally nucleated
Table 1 Clinical and genetic presentation of patients with limb-girdle muscular dystrophy type 2I
Mutation Gender, M:F Age at biopsy, years Onset of disease
a, years Lost ambulation Respiratory aid
L276I/L276I 9:8 44 ± 14 19 ± 11 3 patients No
L276I/Y307N M 35 7 Yes BiPAP
b
L276I/L202Q F 40 4 Yes Respirator
L276I/A157P F 16 3 No No
L276I/P462S F 31 12 Yes No
L276I/Y307N F 13 3 Yes BiPAP
aAge when patient first reported symptoms.
aBilevel positive air pressure.
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visual analog score was used to assess pathological
severity as describedp r e v i o u s l yb yF a n i net al.( 1=
active dystrophic process (marked increase in fiber-size
variability, active degeneration and regeneration, marked
increase in connective tissue); 2 = moderate dystrophic
process (marked increase in fiber-size variability,
increased internal nuclei, few degenerating and regener-
ating fibers, slight increase in connective tissue); and 3 =
mild myopathic picture (moderate increase in fiber-size
variability, increase in internal nuclei)) [17]. Two investi-
gators (SH and TOK), who were blinded to genotype,
assessed all biopsies.
For immunohistochemistry, all sections were fixed in a
1:1 mixture of acetone and methanol or in 4% parafor-
maldehyde (for MyoD), and were subsequently blocked
using 3% FCS in PBS, then stained. Primary antibodies
were diluted in blocking buffer (1:100). To assess the
number of myofibers presently undergoing regeneration,
sections were double-stained with antibodies to nMHC
(Vector Laboratories, Burlingame, CA, USA) and utro-
phin (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Activated satellite cells were visualized with MyoD anti-
bodies (Vector Laboratories), and differentiated satellite
cells (myoblasts) were visualized with myogenin antibo-
dies (clone F5D, developed by Dr Woodring E. Wright,
Developmental Studies Hybridoma Bank, under the aus-
pices of the NICHD and maintained by The University
of Iowa, Iowa City, IA, USA). Size and shape was used
as criteria to separate myogenin-positive atrophic fibers
from myogenin-positive regenerating fibers. All positive
fibers were counted, and calculated as a percentage of
the total number of fibers. To determine the effect of
loss of function of FKRP, we assessed the presence of
glycosylated a-DG (clone VIA4-1, Upstate, Charlottes-
ville, VA, USA), following the manufacturer’sp r o t o c o l .
Alexa 488 and Alexa 594 (Invitrogen, Carlsbad, CA,
USA) secondary anti-mouse and anti-goat antibodies
were used at1:500 dilution in blocking buffer. A micro-
scope with epifluorescence was used for all microscopy
(80i; Nikon, Tokyo, Japan), and pictures were taken
using a 10× objective. Pictures were merged for quantifi-
cation of the entire section.
Statistical analysis
Statistical significance between groups was determined
using Student’s unpaired t-test and P < 0.05 was consid-
ered significant. All numbers provided are mean ± SD.
Linear regression analysis was performed for internal
nuclei versus age (seventeen L276I homozygous patients
and five heterozygous patients) and non-linear regres-
sion analysis for nMHC versus age and duration of ill-
ness (twelve L276I homozygous patients and five
compound heterozygous patients; biopsies from five
homozygous patients were not available for immunohis-
tochemical staining, as only H&E-stained sections were
available). P-values were determined from a Pearson
correlation coefficient table of critical values.
Results
Morphology
The muscle-biopsy sections from the 22 patients had an
average of 729 ± 409 myofibers, whereas those from the
six healthy subjects had 1351 ± 400. We found a four-
fold lower (P < 0.00002) normalized ankle dorsal flexor
force for patients who were compound heterozygous
compared with those homozygous for the L276I muta-
tion (Figure 1A). Patients homozygous for the L276I
mutation had a rather varied pattern of glycosylated a-
dystroglycan staining in the sarcolemma, ranging from
most fibers being positive, to an interspersed pattern
with half the fibers positive and half negative, to very
few positive fibers (Figure 1B). In patients who were
compound heterozygous for the L276I mutation, glyco-
sylated a-dystroglycan was seen in less than 20% of
fibers, with ring fibers staining strongly (Figure 1B).
Compared with healthy normal muscle, H&E-stained
muscle sections from homozygous patients revealed a
mild to severe pathology, whereas the muscle morphol-
ogy of compound heterozygous patients invariably
showed severe pathology (Figure 1C). Pathological sever-
ity was significantly different between groups (Figure
2A), but there were no significant differences in num-
bers of necrotic fibers, ring fibers or internally nucleated
fibers between the homozygous and compound hetero-
zygous patients (Figure 2B-D). Fiber splitting was seen
in three of the homozygous patients and in all of the
compound heterozygous patients. Healthy subjects did
not display any abnormal morphology.
Regeneration
To assess the level of recent regeneration (within the
previous 1 to 4 weeks), we stained for nMHC and utro-
phin. We noted that only small, newly regenerating
myofibers stained positive for both nMHC and utrophin,
whereas mature fibers with internal nuclei stained posi-
tive for nMHC only (Figure 3A-B). The number of
small, newly regenerating fibers positive for both nMHC
and utrophin did not differ significantly between the
groups (Figure 3C). By contrast, the patients who were
compound heterozygous for L276I had approximately
seven times more nMHC-positive/utrophin-negative
myofibers than did homozygous patients (Figure 3D, P <
0.03). A significant difference in nMHC expression
between homozygous and compound heterozygous
patients was seen (Figure 3E, F). To confirm this find-
ing, we stained for the transcription factors that initiate
the myogenic program in satellite cells. Although there
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L276I mutation. (A) Normalized ankle dorsal flexor force was reduced in L276I compound heterozygous (L276I c.h.) versus homozygous (L276I
+/+) patients (*P < 0.003). (B) Immunostaining for the fukutin-related protein (FKRP) substrate, a-dystroglycan (a-DG), showed a uniform
presence in the sarcolemma of healthy controls, whereas it varied in homozygous patients, reflecting the heterogeneity of the disease, and was
mostly restricted to newly formed fibers and ring fibers in compound heterozygous patients. (C) Compared with normal muscle (control), muscle
of both L276 homozygous and compound heterozygous patients displayed internal nuclei, fibrosis and small newly formed regenerating fibers.
The heterogeneous nature of the disease was evident for the patients homozygous for the L276I mutation. (B, C) Bars = 50 μm.
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Page 4 of 10were no MyoD-positive nuclei (data not shown), we
noted that the number of myogenin-positive nuclei in
the compound heterozygous patients trended towards
an increase (P < 0.12), consistent with the nMHC find-
ing (Figure 3G). Neither marker was found in any of the
healthy subjects.
Dual labeling with nMHC and glycosylated a-dystro-
glycan using the VIA4-1 antibody showed that the
majority of small newly formed fibers staining positive
f o rn M H Ca l s os t a i n e dp o s i t i v ef o ra-dystroglycan.
There was an almost inverse staining pattern in groups
of regenerating fibers (Figure 4A-C).
We found no relationship between regeneration in
terms of internally nucleated fibers and clinical severity
and aging (data not shown). However, there was a sig-
nificant relationship (P < 0.005 for all patients) between
nMHC-positive fibers and clinical severity in terms of
ankle dorsal flexion (Figure 5A) and duration of disease
(P < 0.05, Figure 5B). In addition, we noticed a tendency
for nMHC-positive fibers to decline with age in the
L276I homozygous patients (P < 0.052, data not shown).
Immunohistochemistry was carried out on biopsies from
twelve homozygous and five compound heterozygous
patients.
Discussion
Most reports on LGMD2I have dealt with the clinical
presentation and genetics of the disease, but little is
known about the muscle morphology and regeneration
of this disorder. In the absence of a substitute for FKRP,
muscle fibers must rely on regeneration to counterba-
lance ongoing degeneration. In the present study, we
determined the extent of this regeneration and whether
the regenerative response is related to the clinical sever-
ity of LGMD2I, using some of the most commonly used
markers for regeneration.
The key findings of the present study are that the level
of early regeneration, as indicated by nMHC expression,
was higher in patients who were compound heterozy-
gous than in those homozygous for the L276I mutation,
and that this regeneration was related to clinical sever-
ity. In addition, early regeneration tended to decrease
with the duration of illness. Nevertheless, the apparent
higher level of regeneration in compound heterozygous
patients seems to be insufficient to maintain muscle
mass, because the muscle wasting progresses more
rapidly than in homozygous patients. The more severe
phenotype in compound heterozygous patients was
accompanied by a severe depletion of glycosylated a-
dystroglycan. In these patients, a-dystroglycan staining
was generally restricted to small regenerating fibers and
large ring fibers, which is possibly caused by a failed
regenerative process after contractures [18]. This expres-
sion is consistent with previous findings that dystrogly-
can is upregulated during regeneration [19]. In this
study, the sometimes inverse staining pattern we saw
with MHC and a-dystroglycan double-labeling suggests
that as nMHC expression is reducing, the level of glyco-
sylated a-dystroglycan is increasing. Small regenerating
fibers are believed to have added membrane stability
because of increased utrophin and a-7 integrin, hence
the glycosylated a-dystroglycan may persist for a longer
period in these fibers compared with mature fibers
[20,21]. Ultimately, as the protective higher level of pro-
teins important for regeneration starts to decline, the
glycosylated a-dystroglycan presumably disappears. In
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Figure 2 Histopathological evaluation of patients with LGMD2I. (A) The pathological severity score( 1=e x t e n s i v ed e g e n e r a t i o no ft h e
muscle, 2 = moderate pathological changes in morphology, 3 = mild morphological changes), reflecting the overall morphology of the muscle
in terms of degeneration, regeneration, and extent of fatty fibrous-tissue infiltration, shows that there was a significant difference between the
group of patients with LGMD2I homozygous (blue bar) and the group compound heterozygous (red bar) for the L276I mutation. (B-D) There
was no significant difference in number of (B) necrotic fibers, (C) ring fibers or (D) internally nucleated fibers between patients homozygous
(blue bar) and those compound heterozygous (red bar) for the L276I mutation. *P < 0.05.
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autolog of dystrophin, can to some extent substitute for
the missing dystrophin [22,23]. It is not known whether
a functional substitute for FKRP that could delay the
progression of LGMD2I exists, or whether all
glycosylated a-dystroglycan originates from what basic
functionality the mutated FKRP retains.
Although the L276I mutation affects FKRP, it retains
some basic functionality, as suggested by the a-dystro-
glycan staining in homozygous patients. Carriers of
Figure 3 Muscle regeneration in patients with LGMD2I. (A) An illustration of newly regenerating fibers positive for neonatal myosin heavy
chain (nMHC, green) and utrophin (red) (upper row), (B) Repair of mature fiber positive for nMHC and negative for utrophin (lower row). (C) The
percentage of fibers positive for nMHC and utrophin did not differ between patients who were homozygous (n = 12) and those who were
compound heterozygous (n = 5) for L276I. (D) The number of fibers positive for nMHC and negative for utrophin, as seen in fibers undergoing
repair, was higher in compound heterozygous than in homozygous patients (P < 0.03). (E, F) nMHC expression in merged pictures of sections
from (E) representative homozygous and (F) compound heterozygous patients. (G) The number of myogenin-positive nuclei trended towards an
increase in compound heterozygous versus homozygous patients. Bar = 50 μm.
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homozygous for the L276I mutation often have a
milder clinical course than most other patients with
LGMD2I [24]. However, in patients who are com-
pound heterozygous for the L276I mutation, the level
of glycosylated, and thus functional, a-dystroglycan is
further reduced. The glycosylations are vital for inter-
action with the ECM protein laminin a2 (merosin)
thus maintaining sarcolemmal stability [25]. All the
patients who were compound heterozygous for the
L276I mutation in our study are wheelchair users, and
are severely affected by the disorder. Patients who are
compound heterozygous for L276I/P462S and L276I/
Y307N have previously been described as having a
more severe clinical presentation than patients homo-
zygous for L276I [26,27], suggesting that, in most
patients who are compound heterozygous for the
L276I mutation, the other allele carries a mutation
that renders FKRP even more dysfunctional than the
homozygous L276I mutation itself.
Internally nucleated fibers are generally regarded as a
marker for regenerating fibers after injury and muscular
dystrophies, although there are rare exceptions to this
(for example, centronuclear muscular dystrophy caused
by impaired cohesion of the centrosome) [28,29]. In our
study, we found that the number of internally nucleated
fibers alone yielded very little information about the rate
of regeneration, which probably relates to the fact that
internally nucleated fibers can remain located in the
cytoplasm, thus obscuring anyd i f f e r e n c ei nt h er a t eo f
regeneration. This may explain why we did not find any
significant relationship between internal nuclei and clini-
cal severity, as expressed by the force in the muscle that
we examined histologically. The absence of any trend
towards change in internal nuclei throughout the age
span in patients with the L276I mutation could be due
Figure 4 Co-expression of neonatal myosin heavy chain (nMHC) and a-dystroglycan. Many nMHC-positive fibers (A-C) also expressed a-
dystroglycan (A’-C’). An inverse staining pattern was visible in small nMHC-positive fibers. (A) As the level of nMHC decreased, (A’) a-
dystroglycan increased. In a group of regenerating fibers, (B) the level of nMHC was low in all but two fibers whereas (B’) all but one were a-
dystroglycan positive. Within mature fibers, (C) the regenerating nMHC-positive fibers also stained positive for (C’) a-dystroglycan. Bar = 50 μm.
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activity, fairly constant degeneration during the progres-
sion of the disorder, too few patients over a large age
span, or the level of regeneration not being limited by
available satellite cells. This is in contrast to what others
have found in healthy humans; however, those findings
were based on an age-dependent decline in number of
satellite cells and not on actual regeneration [30].
Immunostaining for nMHC is useful in assessing
ongoing regeneration in dystrophic muscle [31-33]. This
MHC isoform has a peak expression within 10 days in
regenerating fibers, thus providing a more precise tem-
poral picture of the ongoing regeneration [34]. Although
nMHC has been shown previously to be present in
atrophic fibers (for example, in spinal muscular atrophy
due to denervation related lack of muscle maturation
[35]), we did not observe any upregulation of nMHC in
atrophic fibers. Other markers for recent regeneration
exist, but no other study has identified a better marker
than nMHC for recent regeneration [36]. By adding
utrophin staining, which is present in varying degrees
on regenerating fibers, but is strongly upregulated in
newly formed fibers, it is possible to see what the pre-
ferred method of regeneration is: repair of fibers and/or
production of new fibers [20]. An increase in nMHC-
positive fibers suggests that regeneration is progressing
at a significantly higher pace in the L276I compound
heterozygous patients, and that regeneration in these
patients is mainly repair of degenerating fibers (nMHC
+/utrophin-) rather than development of new myofibers
(nMHC+/utrophin+). We suggest that the increased
level of nMHC reflects an increased rate of degeneration
in severely affected patients, whereas patients with a
milder phenotype apparently have little need for a high
level of regeneration, because the resistance to structural
stress is higher in the milder than in more severe form
of LGMD2I, in which the fibers are more prone to
degenerate. However, there is a possibility that delayed
maturation is involved in the increased nMHC expres-
sion; that is, that the nMHC persists for longer than
normal [37].
MyoD was not found in any of the muscles in this study.
Presumably because of its short-lived action (<48 hrs) it is
difficult to detect MyoD by immunostaining of muscle tis-
sue [38]. By contrast, myogenin is expressed up to a week
after differentiation of the satellite cells is initiated [39].
The fact that we found myogenin-positive nuclei in the tis-
sue of compound heterozygous patients is consistent with
the increased number of nMHC+/utrophin-myofibers, and
can be interpreted as a constant need for myofiber repair,
that is, a higher rate of regeneration. However, whether
this ultimately leads to exhaustion of the satellite-cell pool
in LGMD2I and contributes to the worsening of the dis-
ease remains to be shown.
The trend towards a decrease in nMHC-positive fibers
with age in L276I homozygous patients may reflect an age-
dependent rather than disorder-dependent decline in rate
of regeneration. This seems inconsistent with the fact that
we were unable to find a relationship between internal
nuclei and age. However, activation of the satellite cells, the
subsequent differentiation of the myoblasts leading to inter-
nal nuclei and the actual repair, although linked, are sepa-
rate events, with the latter heavily dependent on protein
synthesis (nMHC and other proteins), and age may affect
these events differently. In patients who were compound
heterozygous for the L276I mutation, the level of regenera-
tion declined not only with age, but also with duration of
illness. This implies that muscle repair decreases with time
after onset, whereas muscle degeneration continues una-
bated, leading to progressive muscle wasting.
Recent advances in research of DMD therapy and
research on sarcopenia have identified new opportu-
nities for treating a wider field of muscular dystrophies
by boosting the regenerative response, that is, by stimu-
lating satellite-cell activation [40]. Knowledge of the
existing regenerative response in LGMD2I may prove
valuable, as differentiated regeneration may require dif-
ferent approaches for boosting the regenerative response
to avoid adverse side effects, such as depleting the satel-
lite-cell pool.
Conclusions
In this study, we found that although patients with
LGMD2I who were homozygous for the L276I mutation
appeared to have the same level of regeneration as
0
10
20
30
40
50
0 20 40 60 80 100 120
r = 0.75
p < 0.0005
n
M
H
C
+
 
f
i
b
e
r
s
 
%
Normalized ADF force %
Figure 5 Regeneration versus muscle strength.T h e r ew a s sa
significant relationship between regeneration in terms of number of
neonatal myosin heavy chain (nMHC)-positive fibers as a function of
ankle dorsiflexion (ADF) strength in patients with LGMD2I, reflecting
greater need for muscle regeneration in patients who have lost
muscle strength through muscle wasting (squares = patients
homozygous for L276I; triangles = patients compound heterozygous
for L276I).
Krag et al. Skeletal Muscle 2011, 1:31
http://www.skeletalmusclejournal.com/content/1/1/31
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mutation, as determined by level of internally nucleated
fibers, the level of early regeneration, as judged by the
level of neonatal myosin heavy chain, was significantly
higher in the compound heterozygous patients. These
results yield a more accurate picture of the ongoing
degeneration-regeneration cycle.
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